Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1

References

• Anand R, Marmorstein R. Structure and mechanism of lysine-specific demethylase enzymes. J Biol Chem. 2007;282(49):35425–35429.
   PubMed Web of Science ®Google Scholar
• Metzger E, Schule R. The expanding world of histone lysine demethylases. Nat Struct Mol Biol. 2007;14(4):252–254.
   PubMed Web of Science ®Google Scholar
• Pedersen MT, Helin K. Histone demethylases in development and disease. Trends Cell Biol. 2010;20(11):662–671.
   PubMed Web of Science ®Google Scholar
• Johansson C, Tumber A, Che K, et al. The roles of Jumonji-type oxygenases in human disease. Epigenomics. 2014;6(1):89–120.
   PubMed Web of Science ®Google Scholar
• Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12(12):917–930.
   PubMed Web of Science ®Google Scholar
• Bavetsias V, Lanigan RM, Ruda GF, et al. 8-substituted Pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors. J Med Chem. 2016;59(4):1388–1409.
   PubMed Web of Science ®Google Scholar
• Chang KH, King ON, Tumber A, et al. Inhibition of histone demethylases by 4-carboxy-2,2ʹ-bipyridyl compounds. Chem Med Chem. 2010;6(5):759–764.
   Web of Science ®Google Scholar
• Johansson C, Velupillai S, Tumber A, et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol. 2016;12(7):539–545. [cited 2016 May 23]. DOI:10.1038/nchembio.2087
   PubMed Web of Science ®Google Scholar
• King ON, Li XS, Sakurai M, et al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One. 2010;5(11):e15535.
   PubMed Web of Science ®Google Scholar
• Korczynska M, Le DD, Younger N, et al. Docking and linking of fragments to discover jumonji histone demethylase inhibitors. J Med Chem. 2016;59(4):1580–1598.
   PubMed Web of Science ®Google Scholar
• Kruidenier L, Chung CW, Cheng Z, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012;488(7411):404–408.
   PubMed Web of Science ®Google Scholar
• Rose NR, Ng SS, Mecinovic J, et al. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem. 2008;51(22):7053–7056.
   PubMed Web of Science ®Google Scholar
• Rose NR, Woon EC, Kingham GL, et al. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J Med Chem. 2010;53(4):1810–1818.
   PubMed Web of Science ®Google Scholar
• Westaway SM, Preston AG, Barker MD, et al. cell penetrant inhibitors of the kdm4 and kdm5 families of histone lysine demethylases. 1. 3-Amino-4-pyridine carboxylate derivatives. J Med Chem. 2016;59(4):1357–1369.
   PubMed Web of Science ®Google Scholar
• McAllister TE, England KS, Hopkinson RJ, et al. Recent progress in histone demethylase inhibitors. J Med Chem. 2016;59(4):1308–1329.
   PubMed Web of Science ®Google Scholar
• Majamaa K, Hanauske-Abel HM, Gunzler V, et al. The 2-oxoglutarate binding site of prolyl 4-hydroxylase. Identification of distinct subsites and evidence for 2-oxoglutarate decarboxylation in a ligand reaction at the enzyme-bound ferrous ion. Eur J Biochem. 1984;138(2):239–245.
   PubMedGoogle Scholar
• Majamaa K, Turpeenniemi-Hujanen TM, Latipaa P, et al. Differences between collagen hydroxylases and 2-oxoglutarate dehydrogenase in their inhibition by structural analogues of 2-oxoglutarate. Biochem J. 1985;229(1):127–133.
   PubMed Web of Science ®Google Scholar
• Tschank G, Brocks DG, Engelbart K, et al. Inhibition of prolyl hydroxylation and procollagen processing in chick-embryo calvaria by a derivative of pyridine-2,4-dicarboxylate. Characterization of the diethyl ester as a proinhibitor. Biochem J. 1991;275(Pt 2):469–476.
   PubMed Web of Science ®Google Scholar
• Thalhammer A, Mecinovic J, Loenarz C, et al. Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates. Org Biomol Chem. 2010;9(1):127–135.
   PubMed Web of Science ®Google Scholar
• Epitherapeutics APS. Inhibitors of Histone Demethylases. WO2014131777. 2014.
   Google Scholar
• Epitherapeutics APS. Inhibitors of Histone Demethylases. WO2014053491. 2014.
   Google Scholar
• Epitherapeutics APS. Inhibitors of Histone Demethylases. WO2015153498. 2015.
   Google Scholar
• Epitherapeutics APS. Compounds and Methods for Inhibiting Histone Demethylases. US20160102096. 2016.
   Google Scholar
• Demange L, Boeglin D, Moulin A, et al. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1. J Med Chem. 2007 Apr 19;50(8):1939–1957.
   PubMed Web of Science ®Google Scholar
• Yu L, Wang Y, Huang S, et al. Structural insights into a novel histone demethylase PHF8. Cell Res. 2010;20(2):166–173.
   PubMed Web of Science ®Google Scholar
• Nowak RP, Tumber A, Johansson C, et al. Advances and challenges in understanding histone demethylase biology. Curr Opin Chem Biol. 2016 Jun;29(33):151–159.
   Web of Science ®Google Scholar
• Kottakis F, Foltopoulou P, Sanidas I, et al. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. Cancer Res. 2014;74(14):3935–3946.
   PubMed Web of Science ®Google Scholar
• Park SY, Park JW, Chun YS. Jumonji histone demethylases as emerging therapeutic targets. Pharmacol Res. 2016;105:146–151.
   PubMed Web of Science ®Google Scholar
• Tzatsos A, Paskaleva P, Ferrari F, et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest. 2013;123(2):727–739.
   PubMed Web of Science ®Google Scholar
• Thirstrup K, Christensen S, Moller HA, et al. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors. Pharmacol Res. 2011;64(3):268–273.
   PubMed Web of Science ®Google Scholar